



DEPARTMENT OF HEALTH & HUMAN SERVICES

#15  
Public Health Service

Food and Drug Administration  
Rockville MD 20857

DEC 22 1988

Re: Naftin  
Docket No. 88E-0183

Charles E. Van Horn, Esq.  
Deputy Solicitor  
Solicitor's Office  
U.S. Patent and Trademark Office  
Washington, DC 20231

**SOLICITOR**

DEC 28 1988

U.S. PATENT & TRADEMARK OFFICE

Dear Mr. Van Horn:

This is in regard to the patent term extension application for U.S. Patent No. 4,282,251 filed by Sandoz Pharmaceuticals Corp., under 35 U.S.C. 156. The patent claims the human drug product named Naftin, New Drug Application (NDA) number 19-599.

In the June 24, 1988 issue of the Federal Register, the Food and Drug Administration published its determination of the product's regulatory review period, as required under 35 U.S.C. 156(d)(2)(A). The notice provided that on or before December 21, 1988, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to the notice regarding Naftin has expired, and FDA has received no such petition. FDA, therefore, considers Naftin's regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Ronald L. Wilson  
Director  
Health Assessment Policy Staff  
Office of Health Affairs

cc: Gerald D. Sharkin, Esq.  
Patent and Trademark Affairs  
Sandoz Pharmaceuticals Corp.  
59 Route 10  
East Hanover, NJ 07936